Novartis AG Hopes Its Cancer Portfolio Will Impress

Novartis has announced plans to showcase new drug development data at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) annual meeting this month. The company will be giving more than 160 presentations on breast cancer and haematology treatments at the two conferences, which will showcase major advances in the field. SABCS highlights will include phase III data on everolimus for advanced breast cancer, as well as further findings on Zometa and BKM120.

Back to news